Stock Market News4 months Piper Sandler downgrades Biogen, slashes PT by $177 amid transition challenges Investing.com
4 months Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term Zacks
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here’s why you should take advantage.
4 months Beaten Down Biogen Stock Looks Attractive At Current Levels Seeking Alpha
5 months BMO cuts rating on Merck and Biogen, on lack of near term catalyst Investing.com
5 months Stifel downgrades Biogen on slow Alzheimer’s drug launch, uncertainty ahead Investing.com
5 months Private Medicare plans must cover Biogen’s ALS drug, US agency says Investing.com
5 months Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock Zacks
Though there is uncertainty about Biogen’s sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.
5 months Biogen cut at Jefferies as ‘2025 has a tough setup’ Investing.com
5 months Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript Seeking Alpha
6 months Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe Zacks
The CHMP renders a positive opinion recommending approval for BIIB and Eisai’s Leqembi for treating early Alzheimer’s disease.
6 months Here’s Why Biogen Inc. (BIIB) is a Strong Value Stock Zacks
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here’s why you should take advantage.
6 months Are Investors Undervaluing Biogen (BIIB) Right Now? Zacks
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
6 months Biogen Q3 Earnings Review: Why I Remain Optimistic Despite Difficult Quarter Seeking Alpha
6 months Biogen Beats on Q3 Earnings & Sales, Raises ’24 EPS View Zacks
BIIB’s Q3 earnings and sales beat estimates. The company raises its EPS guidance for 2024 by 35 cents.
6 months Biogen Inc. (BIIB) Q3 2024 Earnings Call Transcript Seeking Alpha
6 months Biogen lifts annual profit forecast as new treatments boost earnings Investing.com
6 months Biogen (NASDAQ:BIIB) Releases FY 2024 Earnings Guidance MarketBeat
Biogen (NASDAQ:BIIB) updated its FY 2024 earnings guidance. The company provided EPS guidance of 16.100-16.600 for the period, compared to the consensus estimate of 16.190.
6 months Short Interest in Biogen Inc. (NASDAQ:BIIB) Grows By 7.7% MarketBeat
Biogen Inc. (NASDAQ:BIIB – Get Free Report) was the target of a large increase in short interest in October. As of October 15th, there was short interest totalling 3,070,000 shares, an increase of 7.7% from the September 30th total of 2,850,000 shares…
6 months Biogen raises annual profit forecast as new treatments boost earnings Investing.com
6 months Biogen Sinks. Why A Surprise Boost From Its Alzheimer’s Drug Wasn’t Enough. Investor's Business Daily
Biogen stock dipped Wednesday despite an unexpected boost from its new Alzheimer’s drug, Leqembi, and an earnings guidance hike.
The post Biogen Sinks. Why A Surprise Boost From Its Alzheimer's Drug Wasn't Enough. appeared first on Investor&#…
6 months Alphabet, Biogen, Humana rise premarket; AMD, Eli Lilly fall Investing.com
6 months Biogen (NASDAQ:BIIB) Sees Unusually-High Trading Volume – Here’s What Happened MarketBeat
Biogen (NASDAQ:BIIB) Sees Unusually-High Trading Volume – Here’s What Happened
7 months Greenleaf Trust Sells 3,475 Shares of Biogen Inc. (NASDAQ:BIIB) MarketBeat
Greenleaf Trust cut its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 57.1% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,606 sha…
7 months Will New Drugs Help Biogen Surpass Q3 Earnings Estimates? Zacks
In the third quarter, lower sales of BIIB’s multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.
7 months International Assets Investment Management LLC Has $695.87 Million Stake in Biogen Inc. (NASDAQ:BIIB) MarketBeat
International Assets Investment Management LLC raised its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 19,722.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35…
7 months The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen Zacks
Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen are included in this Analyst Blog.
7 months The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen Zacks
Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen are included in this Analyst Blog.
7 months Biogen Inc. (NASDAQ:BIIB) Shares Bought by Raymond James & Associates MarketBeat
Raymond James & Associates boosted its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 3.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 192,0…
7 months Arlington Partners LLC Acquires 4,902 Shares of Biogen Inc. (NASDAQ:BIIB) MarketBeat
Arlington Partners LLC increased its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 34.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,214 sha…
The Stock Market News
The Stock Market News is a financial news aggregator for traders and investors that proposes to you the latest breaking news headlines on global financial markets, economy and business. Live qoute and chart technical analysis, opinion, price forecast on current stock market, currencies (Forex), cryptocurrency, commodities futures, ETFs, funds, bonds and more. Disclaimer: by using any material of this website, you acknowledge and agree that TheStockMarketNews.com is not responsible for the content, actions or any legal issues arising from third-party websites; materials of this website are not financial advice or call to actions. Trading and investing in financial instruments involve high risks including the risk of investment loss.